Invokana® (canagliflozin) The FDA has approved the first-in-class sodium glucose cotransporter 2 (SGLT2) inhibitor, canagliflozin. Find out all about this new drug — mode of action, contraindications, side effects, weight loss, lower A1c’s, blood pressure and its effect on cholesterol — with this handout for medical professionals. Just follow this …

Researchers compared two incentive scenarios: in the first one, employees got $100 for each month they met the goal of dropping at least one pound per week; while in the second, $500 was set aside each month for a group of five co-workers and group who met their goal split …

Researchers found that even those with mild symptoms of psoriasis face a significant risk for diabetes. They analyzed data from a populational cohort of participants 10 years of age or older in January 1997 and followed through December 2009. Of the 4,614,807 subjects studied, 52,613 patients had psoriasis, including 6,784 …

Researchers presented a study at an AHA meeting which found that adults who consumed canola or high-oleic canola oils on a daily basis for four weeks lowered their belly fat by 1.6%. Abdominal fat was unchanged by the other three oils studied, which included a flax/safflower oil blend, corn/safflower oil …

The FDA has approved Invokana (canaglifozin), the first in its class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Johnson & Johnson’s new drug is used to treat type 2 diabetes in conjunction with diet and exercise….

Worms treated with metformin live longer. The drug may slow the aging process by mimicking the effects of dieting….

An increase in dietary fat can raise glucose levels and insulin requirements in patients with type 1 diabetes….

Metformin delays aging and cancer progression by reducing the production of….

Marijuana used regularly has little impact on the overall metabolism of glucose and lipids….

A study focused on social networking and support groups showed the effects of these programs on blood sugar levels are short-term….